Therapeutics

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Paul Jannetto, Ph.D., associate professor of laboratory medicine and pathology at Mayo Clinic, and discusses how CBD can affect your health, what the medical benefits are, and its impact on urine drugs of abuse testing.

Loralie Langman, Ph.D., explains the difference between chain of custody and clinical toxicology testing. Chain of custody is a process used for toxicology testing when the results might have legal implications for the individual tested. Clinical toxicology testing is used for routine medical care. Mayo Clinic Laboratories offers a full range of clinical and forensic toxicology testing.

Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.

Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and therapeutic drug monitoring can guide clinicians to the most-effective treatment for each patient.

Bringing together advanced testing technology, unparalleled expertise, and a patient-focused approach, Mayo Clinic Laboratories’ new high-resolution urine drug testing profile, ADMPU, evaluates for 22 drug classes including alcohol, marijuana, and nicotine, enabling clarity on substance use and precision insights that propel treatment.

Partnering with Mayo Clinic has helped St. Clair Health improve patient care and gain a new competitive advantage in pharmacogenetics.

John Black, M.D., co-director of the Personalized Genomics Lab at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with Bobbi Pritt, M.D., about mental health awareness. In this episode, Dr. Black and Dr. Pritt review key takeaways from Mental Health Awareness Month, the role that lab testing plays in mental health, and the robust science behind treatment.

Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.

In this month's "Hot Topic," Paul Jannetto, Ph.D., identifies how to determine new vs. residual use of marijuana in a patient, and teaches how to calculate the carboxy-tetrahydrocannabinol (carboxy-THC) to creatinine ratio along with a decision ratio by demonstrating its clinical utility via case study.

Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the use of qualitative urine screening assays and quantitative confirmatory testing to determine compliance in pain management patients.

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted stimulant and PCP screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed CNS stimulant medications.

In this episode, Paul Jannetto, Ph.D., associate professor of laboratory medicine and pathology and director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab at Mayo Clinic, discusses how his three labs support toxicology testing for patient care.